Milena Salerno Selected Research

Acute Erythroblastic Leukemia (Erythroleukemia)

6/2019	Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
3/2018	Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
11/2014	Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.
1/2013	New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).
2/2010	Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.
2/2009	N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors.
2/2007	Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors.
11/2005	Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Milena Salerno Research Topics

Disease

8	Acute Erythroblastic Leukemia (Erythroleukemia) 06/2019 - 11/2005
4	Alzheimer Disease (Alzheimer's Disease) 05/2015 - 05/2006
2	Amyloid Plaque 05/2013 - 05/2006
2	Neoplasms (Cancer) 02/2006 - 01/2003
2	Acute Promyelocytic Leukemia 01/2003 - 04/2002
1	Breast Neoplasms (Breast Cancer) 06/2019
1	Leukemia 06/2019
1	Cutaneous Leishmaniasis 01/2008
1	Lung Neoplasms (Lung Cancer) 03/2007
1	Syphilis 01/2003
1	Communicable Diseases (Infectious Diseases) 01/2003

Drug/Important Bio-Agent (IBA)

6	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2019 - 02/2009
6	pirarubicinIBA 06/2019 - 02/2009
3	multidrug resistance-associated protein 1IBA 06/2019 - 01/2003
3	Amyloid (Amyloid Fibrils)IBA 05/2015 - 05/2006
2	Peptides (Polypeptides)IBA 05/2015 - 03/2007
2	MetalsIBA 05/2013 - 01/2013
2	AnthracyclinesIBA 02/2007 - 11/2005
2	Arsenic Trioxide (Trisenox)FDA Link 01/2003 - 04/2002
1	EstersIBA 06/2019
1	Proteins (Proteins, Gene)FDA Link 06/2019
1	Carrier Proteins (Binding Protein)IBA 06/2019
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 05/2015
1	GD3 ganglioside (GD(3))IBA 05/2013
1	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 05/2013
1	IonsIBA 05/2013
1	ZincIBA 01/2013
1	CopperIBA 01/2013
1	ThiosemicarbazonesIBA 01/2013
1	Meglumine AntimoniateIBA 01/2008
1	betadex (beta-cyclodextrin)IBA 01/2008
1	Pharmaceutical PreparationsIBA 01/2008
1	Amyloid beta-PeptidesIBA 03/2007
1	thioflavin TIBA 05/2006
1	Cisplatin (Platino)FDA LinkGeneric 02/2006
1	Verapamil (Calan)FDA LinkGeneric 11/2005
1	AntimonyIBA 01/2003
1	Anti-Infective Agents (Microbicides)IBA 01/2003
1	Arsenicals (Arsenic Compounds)IBA 01/2003
1	ArsenicIBA 01/2003
1	SaltsIBA 04/2002
1	MetalloidsIBA 04/2002